CAMBRIDGE, Mass., March 5, 2018 /PRNewswire/ -- Merrimack
Pharmaceuticals, Inc. (Nasdaq: MACK) today announced that the
company will host its fourth quarter and full year 2017 investor
conference call and webcast at 8:30 a.m. ET on Monday, March 12, 2018.
The call will cover an update on Merrimack's recent progress as
well as a summary of fourth quarter and full year 2017 financial
results. A press release detailing the information to be discussed
on the call will be issued the morning of Monday, March 12, 2018. Investors and the general
public are invited to listen to the call by dialing (877) 564-1301
(domestic) or (224) 357-2394 (international) five minutes prior to
the start of the call and providing the passcode 8074029.
In addition, the company today announced that Richard Peters, M.D., Ph.D., President and Chief
Executive Officer, is scheduled to present at the Cowen
38th Annual Health Care Conference on Tuesday, March 13, 2018, at 10:40 a.m. ET in Boston, MA.
Live, listen-only webcasts of the fourth quarter and full year
2017 investor conference call and the company's presentation at the
Cowen 38th Annual Health Care Conference can be accessed
under "Events and Presentations" in the Investors section of
Merrimack's website, investors.merrimack.com. A replay of the
fourth quarter and full year 2017 investor conference call will be
archived there for approximately six weeks. A replay of the
conference presentation will be archived there for approximately 30
days.
About Merrimack
Merrimack is a biopharmaceutical company based in Cambridge, Massachusetts that is outthinking
cancer to ensure that patients and their families live fulfilling
lives. Its mission is to transform cancer care through the smart
design and development of targeted solutions based on a deep
understanding of cancer pathways and biological markers. All of
Merrimack's development programs, including four clinical studies
and six candidates in preclinical development, fit into its
strategy of 1) understanding the biological problems it is trying
to solve, 2) designing specific solutions and 3) developing those
solutions for biomarker-selected patients. This three-pronged
strategy seeks to ensure optimal patient outcomes. For more
information, please visit Merrimack's website at
www.merrimack.com.
Forward Looking Statements
Any statements in this press release about future expectations,
plans and prospects for Merrimack constitute forward-looking
statements within the meaning of The Private Securities Litigation
Reform Act of 1995, as amended. Actual results may differ
materially from those indicated by such forward-looking statements.
Merrimack anticipates that subsequent events and developments will
cause its views to change. However, while Merrimack may elect to
update these forward-looking statements at some point in the
future, Merrimack specifically disclaims any obligation to do
so.
Contact:
Geoffrey
Grande, CFA
617-441-7602
ggrande@merrimack.com
View original
content:http://www.prnewswire.com/news-releases/merrimack-announces-timing-of-full-year-2017-investor-conference-call-and-presentation-at-the-cowen-health-care-conference-300607802.html
SOURCE Merrimack Pharmaceuticals, Inc.